Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib

PURPOSE: Vandetanib is well-tolerated in patients with advanced medullary thyroid carcinoma (MTC). Long-term outcomes and mechanisms of MTC progression have not been reported previously. DESIGN: We monitored toxicities and disease status in patients taking vandetanib for hereditary, advanced MTC. Tu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Kraft, Ira L, Akshintala, Srivandana, Zhu, Yuelin, Lei, Haiyan, Derse-Anthony, Claudia, Dombi, Eva, Steinberg, Seth M, Lodish, Maya, Waguespack, Steven G, Kapustina, Oxana, Fox, Elizabeth, Balis, Frank M, Merino, Maria J, Meltzer, Paul S, Glod, John W, Shern, Jack F, Widemann, Brigitte C
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5815946/
https://ncbi.nlm.nih.gov/pubmed/29187393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2101
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak